ArticleJournal of clinical laboratory analysis2026
Strategies for Monitoring Serum Protein Degradation With an Antibody Array-Based Technology.
Article in Journal of clinical laboratory analysis, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundHuman serum is an ideal body fluid for discovering and monitoring biomarkers for disease diagnosis and treatment response. However, intrinsic proteolytic degradation during sample handling may compromise biomarker integrity, which may affect the accuracy of results. To address this issue, we aimed to test the feasibility of using antibody array technology to evaluate the temporal stability of serum proteins at room temperature.
methodsConcentrations of 480 serological proteins were monitored using antibody arrays in samples from 10 healthy donors incubated at 25°C for 0, 6, 12, 24, and 48 h. Linear regression assessed time-dependent concentration changes. Physicochemical properties (molecular weight, isoelectric point, instability index, aliphatic index, hydropathicity) of the proteins were analyzed. Enrichment analyses were performed on degraded proteins.
resultsDuring 48-h incubation, 201 proteins showed a significant negative linear correlation between concentration and time, among which the concentration of 91 proteins reduced over 20% in the first 6 h. Degraded proteins were significantly associated with lower molecular weight (MW < 40 kDa) but no other physicochemical properties. Enrichment analyses revealed degraded proteins associated with various terms and involved in important signaling pathways, like JAK-STAT, PI3K-Akt, and MAPK.
conclusionOur data demonstrate the feasibility of employing antibody arrays for detecting serum protein degradation. Using this platform, we found some serum proteins with clinical significance rapidly degrade at room temperature, including interleukins (e.g., IL-1β/IL-12p40/IL-17), growth factors (e.g., aFGF, bFGF, and BMP-2), and chemokines (e.g., I-309, 6Ckine, and BLC). These may serve as potential biomarkers for assessing human serum sample quality.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.